Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00024492 · ClinicalTrials.gov registry record · Phase 1
Study of Liposome Encapsulated Mitoxantrone (LEM) in Patients With Advanced Cancer
A Phase 1 study of Tumors, sponsored by INSYS Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT00024492: Completed Phase 1 study of Tumors, sponsored by INSYS Therapeutics.
NCT00024492 is a Phase 1 study of Tumors that has completed, run by INSYS Therapeutics. The registered enrollment target is 40 participants, below the 197-participant average among 20 other Tumors trials with a reported enrollment target (80% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00024492, a Phase 1 study of Tumors, has completed, sponsored by INSYS Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
Liposome entrapped mitoxantrone (LEM) is a mixture of commercially available mitoxantrone HCL (Novantrone) and a combination of lyophilized lipids. Mitoxantrone, the active agent in the investigational formulation, is a currently marketed chemotherapeutic agent. The rationale for development of liposomal formulations is primarily that of improving the safety profile of the drug, which may permit dose intensification and/or an increase in the cumulative dose that may be administered, resulting in enhanced efficacy. LEM will be given to patients with advanced solid tumors to determine the dose of drug these patients can tolerate. Patients will receive intravenous LEM every 21 days until the disease progresses or toxicity occurs requiring treatment discontinuation. Anti-tumor effects of LEM will be assessed and patients will be evaluated for safety and tolerability.
Conditions Studied
Interventions
- DRUG Liposome Encapsulated Mitoxantrone (LEM)
Study Locations (4)
California
- City of Hope National Medical Center - Duarte
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
Ohio
- The Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2001-08 |
| Est. Completion | 2004-06 |
| Phase | Phase 1 |
What the finished NCT00024492 record still lists
NCT00024492 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 197-participant average among 20 other Tumors trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Tumors appearing as the primary indexed condition, and to 1 intervention - of which Liposome Encapsulated Mitoxantrone (LEM) is the first listed.
NCT00024492 reports a single indexed study location in California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT00024492 about?
NCT00024492 is a clinical study titled "Study of Liposome Encapsulated Mitoxantrone (LEM) in Patients With Advanced Cancer". Liposome entrapped mitoxantrone (LEM) is a mixture of commercially available mitoxantrone HCL (Novantrone) and a combination of lyophilized lipids. Mitoxantrone, the active agent in the investigational formulation, is a currently marketed chemotherapeutic agent. The rationale for development of lipo...
What is the current status of trial NCT00024492?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2001-08. Estimated completion is 2004-06.
What conditions does trial NCT00024492 study?
This clinical trial studies the following conditions: Tumors.
What interventions are being tested in trial NCT00024492?
The interventions under investigation include: Liposome Encapsulated Mitoxantrone (LEM) (DRUG).
Who is sponsoring clinical trial NCT00024492?
This trial is sponsored by INSYS Therapeutics, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00024492 being conducted?
This trial has 4 study locations across California, Florida, Michigan, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00024492's enrollment target sits among peer trials
40 13th of 20 higher than 8 of 20 other Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
HP Pyruvate MRI in Cancers
RECRUITING · Phase 1
-
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
COMPLETED · Phase 1
-
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
COMPLETED · Phase 1
-
Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia